Oric Pharmaceuticals, Inc.: EcoR1 Capital, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
EcoR1 Capital, LLC amended its Schedule 13G stake filing for Oric Pharmaceuticals, Inc., according to SEC accession 0000935836-26-000590. The filing updates the investor's reported ownership position in the clinical-stage oncology company. Schedule 13G amendments are typically filed when a passive investor's stake crosses or adjusts around the 5% threshold, though the headline did not disclose the revised share count or percentage. The change matters because it signals a shift in a major institutional holder's exposure to Oric. Investors will watch for the amended filing's details on share count and ownership percentage, and for any subsequent 13F or 13G updates.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Oric Pharmaceuticals, Inc., EcoR1 Capital, LLC